Karyopharm's controversial Xpovio could see wider market by Angus Liu Tuesday, March 10, 2020 Thanks to a new clinical win, Karyopharm's Xpovio looks on track to enter earlier use—and access a broader market opportunity.
Karyopharm's Xpovio nabs FDA nod despite checkered past by Angus Liu Monday, July 8, 2019 The FDA defied an expert panel's call to delay approval on safety issues, at least until phase 3 data debuts later this year.
